Zaizhu Zhang, Nina Zhou, Hua Zhu, Zhi Yang. Clinical application and new progress of 18F-FDG PET/MRI in pancreatic cancer[J]. Int J Radiat Med Nucl Med, 2022, 46(4): 235-239. DOI: 10.3760/cma.j.cn121381-202103032-00164
Citation: Zaizhu Zhang, Nina Zhou, Hua Zhu, Zhi Yang. Clinical application and new progress of 18F-FDG PET/MRI in pancreatic cancer[J]. Int J Radiat Med Nucl Med, 2022, 46(4): 235-239. DOI: 10.3760/cma.j.cn121381-202103032-00164

Clinical application and new progress of 18F-FDG PET/MRI in pancreatic cancer

  • Pancreatic cancer is a malignant tumor with high malignant degree, easy metastasis, rapid progression and poor prognosis, so early diagnosis, accurate staging and timely efficacy evaluation are crucial for patients with pancreatic cancer. As a novel multimodality imaging technology, integrated PET/MRI combines with high resolution for soft-tissue, multi-sequences, multi-parameters of MRI and high sensitivity of PET metabolic imaging, it has potential application value in tumor staging, efficacy evaluation, prognosis prediction, and recurrence monitoring of pancreatic cancer patients. Therefore, this paper reviews the advantages of 18F-fluorodeoxyglucose (FDG) PET/MRI and its clinical application and new progress in pancreatic cancer.
  • loading

Catalog

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return